Founded in 2018, Character has raised capital from leading investors at the intersection of healthcare and technology, including an oversubscribed $110+ million Series B in 2025 co-led by aMoon and Luma Group, with participation from Bausch + Lomb, Innovation Endeavors, Sanofi Ventures, Catalio Capital Management, S32, KdT Ventures, and Jefferson Life Sciences. Key Responsibilities: Contribute to the implementation of models and analyses to support Character Bio''s drug discovery and development activities, including quantitative biomarker from imaging and phenotype development, disease progression and time-to-event (survival) modeling, and real-world-data analyses.